Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group - PubMed (original) (raw)
Clinical Trial
. 1981 Oct 15;48(8):1705-10.
doi: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4.
S Frytak, R G Hahn, M J O'Connell, R J Reitemeier, J Rubin, A J Schutt, L H Weiland, D S Childs, M A Holbrook, P T Lavin, E Livstone, H Spiro, A Knowlton, M Kalser, J Barkin, H Lessner, R Mann-Kaplan, K Ramming, H O Douglas Jr, P Thomas, H Nave, J Bateman, J Lokich, J Brooks, J Chaffey, J M Corson, N Zamcheck, J W Novak
- PMID: 7284971
- DOI: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4
Clinical Trial
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group
C G Moertel et al. Cancer. 1981.
Abstract
One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU. Median survival with radiation alone was only 51/2 months from date of diagnosis. Both 5-FU-containing treatment regimens produced a highly significant survival improvement when compared with radiation alone. Forty percent of patients treated with the combined regimens were still living at one year compared with 10% of patients treated with radiation only. Survival differences between 4000 rads plus 5-FU and 6000 rads plus 5-FU were not significant with an overall median survival of ten months. Significant prognostic variables, in addition to treatment, were pretreatment performance status and pretreatment CEA level.
Similar articles
- Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K. Ardalan B, et al. Cancer. 1994 Oct 1;74(7):1869-73. doi: 10.1002/1097-0142(19941001)74:7<1869::aid-cncr2820740707>3.0.co;2-j. Cancer. 1994. PMID: 8082092 Clinical Trial. - [Combination radiotherapy and chemotherapy in cancer of the pancreas. Review of the literature and prospects].
Reboul F, Serin D, Martin D, Plat F. Reboul F, et al. Bull Cancer. 1990;77(3):275-81. Bull Cancer. 1990. PMID: 2187546 Review. French. - Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC, Iott MJ, Corsini MM. Miller RC, et al. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):364-8. doi: 10.1016/j.ijrobp.2008.11.069. Int J Radiat Oncol Biol Phys. 2009. PMID: 19735864 Review.
Cited by
- Advanced-stage pancreatic cancer: therapy options.
Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Werner J, et al. Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30. Nat Rev Clin Oncol. 2013. PMID: 23629472 Review. - The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. Goldstein D, et al. Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134511 Free PMC article. Clinical Trial. - Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Herman JM, et al. J Clin Oncol. 2013 Mar 1;31(7):886-94. doi: 10.1200/JCO.2012.44.7516. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341531 Free PMC article. Clinical Trial. - Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z, Ma XJ, Long J, Xu J, Jiang GL. Wang Z, et al. Radiat Oncol. 2015 Jan 10;10:14. doi: 10.1186/s13014-014-0312-5. Radiat Oncol. 2015. PMID: 25575617 Free PMC article. Clinical Trial. - Overview of chemotherapy for pancreatic cancer.
Arbuck SG. Arbuck SG. Int J Pancreatol. 1990 Aug-Nov;7(1-3):209-22. doi: 10.1007/BF02924239. Int J Pancreatol. 1990. PMID: 2081925 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical